MENU
+Compare
PHAR
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$10.26
Change
+$0.07 (+0.69%)
Capitalization
696.5M

PHAR Pharming Group NV Forecast, Technical & Fundamental Analysis

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases... Show more

PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PHAR with price predictions
Jul 25, 2025

PHAR in upward trend: price expected to rise as it breaks its lower Bollinger Band on July 07, 2025

PHAR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where PHAR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where PHAR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 23, 2025. You may want to consider a long position or call options on PHAR as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAR advanced for three days, in of 182 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

PHAR moved below its 50-day moving average on July 09, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PHAR crossed bearishly below the 50-day moving average on July 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PHAR entered a downward trend on July 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHAR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.279) is normal, around the industry mean (18.053). P/E Ratio (0.000) is within average values for comparable stocks, (59.920). PHAR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.580). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.524) is also within normal values, averaging (280.104).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PHAR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PHAR is expected to report earnings to fall 94.32% to -1 cents per share on July 31

Pharming Group NV PHAR Stock Earnings Reports
Q2'25
Est.
$-0.01
Q1'25
Missed
by $0.21
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.02
Q2'24
Missed
by $0.02
The last earnings report on May 08 showed earnings per share of -21 cents, missing the estimate of 0 cents. With 13.04K shares outstanding, the current market capitalization sits at 696.50M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Darwinweg 24
Phone
+31 715247400
Employees
332
Web
https://www.pharming.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRCVX21.67N/A
N/A
Carillon Eagle Growth & Income A
SGSCX32.48N/A
N/A
DWS Global Small Cap S
JMEEX67.01N/A
N/A
JPMorgan Mid Cap Equity R5
BMCKX26.89N/A
N/A
BlackRock Advantage Large Cap Gr K
MSDOX14.07N/A
N/A
Morgan Stanley Emerging Mkt ex China C

PHAR and Stocks

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+0.67%
APLM - PHAR
31%
Poorly correlated
+1.30%
ADPT - PHAR
27%
Poorly correlated
+0.84%
IBRX - PHAR
27%
Poorly correlated
-4.98%
ATXS - PHAR
26%
Poorly correlated
+1.37%
SONN - PHAR
25%
Poorly correlated
-5.45%
More